Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q4 2018 · 10-K
Revenue$163.07K$163.07K−42.3% vs Q4 2017 Net Income-$2.01M-$2.01MN/M vs Q4 2017 EPS Diluted-$0.11-$0.11N/M vs Q4 2017 Operating Income-$2,021,139N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$387,538N/M Margins · derivedOperating margin-1239.5%+1622.0 pt vs Q4 2017
Net margin-1231.9%+1606.8 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 6, 2019 · 65 d after period end